KeraVision
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application for the firm's KeraVision reversible vision correction implant ring, filed by FDA in August, is slated to be reviewed by the agency's Ophthalmic Devices Panel at a Jan. 12 meeting, the firm reports. The Fremont, California company expects to debut the device in 1999 with a moderate myopia indication ("The Gray Sheet" Nov. 16, p. 25)